Morgan Stanley & Co. Int'l plc Rule 38.5- ALLERGAN PLC (8426Y)

TIDM48QN TIDM0Y7T

RNS Number : 8426Y

Morgan Stanley & Co. Int'l plc

06 January 2020

FORM 38.5

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2007 (AS AMENDED)

DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS

   1.             KEY INFORMATION 
 
 Name of exempt market-maker            Morgan Stanley & Co. International 
                                         plc 
 Company dealt in                       ALLERGAN PLC 
                                      ------------------------------------ 
 Class of relevant security to         US$0.0001 ORDINARY SHARES 
  which the dealings being disclosed 
  relate (Note 1) 
                                      ------------------------------------ 
 Date of dealing                        03 JANUARY 2020 
                                      ------------------------------------ 
 
   2.             DEALINGS (Note 2) 
   (a)           Purchases and sales 
 
 Total number of relevant   Highest price paid   Lowest price paid (Note 
  secuities accquired        (Note 3)             3) 
 969                        191.0800 USD         190.2600 USD 
                           -------------------  ------------------------ 
 
 
 Total number of relevant   Highest price paid   Lowest price paid (Note 
  secuities disposed         (Note 3)             3) 
 969                        191.0800 USD         190.2558 USD 
                           -------------------  ------------------------ 
 
   (b)           Derivatives transactions (other than options transactions) 
 
 Product name,   Nature of transaction   Number of relevant   Price per unit 
  e.g. CFD        (Note 4)                securities 
                                          (Note 5) 
 N/A             N/A                     N/A                  N/A 
                ----------------------  -------------------  --------------- 
 
   (c)            Options transactions in respect of existing relevant securities 
   i)           Writing, selling, purchasing or varying 
 
 Product        Writing,       Number           Exercise   Type, e.g    Expiry   Option 
  name, eg       selling,       of securities    Price      American,    Date     money paid/received 
  call option    purchasing,    to which                    European              per unit 
                 varying        the option                  etc                   (Note 3) 
                 etc            relates 
                                (Note 5) 
 N/A            N/A            N/A              N/A        N/A          N/A      N/A 
               -------------  ---------------  ---------  -----------  -------  --------------------- 
 

(ii) Exercising

 
 Product name, eg call   Number of securities   Exercise price per 
  option                                         unit (Note 3) 
 N/A                     N/A                    N/A 
                        ---------------------  ------------------- 
 

3. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 
 Full Details of any agreement, arrangement or understanding between 
  the person disclosing and any other person relating to the voting 
  rights of any relevant securities under any option referred to 
  on this form or relating to the voting rights or future acquisition 
  or disposal of any relevant securities to which any derivative 
  referred to on this form is referenced. If none, this should 
  be stated. 
 
 
 
 Date of disclosure              06 JANUARY 2020 
 Contact Name                   Craig Horsley 
                                ----------------- 
 Telephone Number               [phone] 
                                ----------------- 
 Name of offeree/offeror with   ABBVIE INC. 
  which connected 
                                ----------------- 
Nature of connection (Note 6)   Advisory 
                                ----------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ISESSAFSMESSEFF

(END) Dow Jones Newswires

January 06, 2020 05:19 ET (10:19 GMT)